SkinBioTherapeutics (LON:SBTX) Issues Quarterly Earnings Results

SkinBioTherapeutics (LON:SBTX) issued its earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) EPS for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

SkinBioTherapeutics Price Performance

Shares of LON SBTX opened at GBX 22.20 ($0.29) on Wednesday. The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01. The stock has a market capitalization of £50.71 million, a price-to-earnings ratio of -13.65 and a beta of 2.01. The firm’s 50 day simple moving average is GBX 19.67 and its 200-day simple moving average is GBX 16.46. SkinBioTherapeutics has a 12 month low of GBX 8.32 ($0.11) and a 12 month high of GBX 26.45 ($0.34).

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.